Prospects of the clinical utilization of melatonin

NeuroSignals

Volumn 7, Issue 4, 1998, Pages 195-219

  Bubenik, George A ^a   Blask, David E ^b   Brown, Gregory M ^c   Maestroni, Georges J M ^d   Pang, Shiu Fun ^e   Reiter, Russel J ^f   Viswanathan, Mohan ^g   Zisapel, Nava ^h  

^a UNIVERSITY OF GUELPH   (Canada)

^b BASSETT RESEARCH INSTITUTE   (United States)

^c CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^d INSTITUTE OF PATHOLOGY   (Switzerland)

^e UNIVERSITY OF HONG KONG   (Hong Kong)

^f University of Texas Health Science Center ^*  (United States)

^g GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^h TEL AVIV UNIVERSITY   (Israel)

Author keywords

Antioxidants; Cancer; Cardiovascular disease; Clinical studies; Gastrointestinal disorders; Immunopharmacology; Insomnia; Melatonin; Migraine; Receptors; Reproduction; Sleep; Temperature

Indexed keywords

ANTIOXIDANT; BRAIN RECEPTOR; CYTOSTATIC AGENT; FREE RADICAL; INTERLEUKIN 2; MELATONIN; MELATONIN RECEPTOR; SCAVENGER;

ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; ARTERY TONE; BIOLOGICAL RHYTHM; BLINDNESS; BLOOD BRAIN BARRIER; BRAIN ARTERY; COLITIS; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; DISEASE MARKER; DRUG MECHANISM; GASTROINTESTINAL DISEASE; GONAD; GRAM NEGATIVE INFECTION; HEMATOPOIESIS; HEMORRHAGIC SHOCK; HORMONE DEFICIENCY; HUMAN; IMMUNE DEFICIENCY; IMMUNOPHARMACOLOGY; INSOMNIA; JET LAG; NONHUMAN; PUBERTY; REVIEW; SEASONAL VARIATION; SEPTIC SHOCK; SHIFT WORKER; SLEEP DISORDER; STOMACH ULCER; STRESS; THERMOREGULATION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; ANTIOXIDANTS; CIRCADIAN RHYTHM; CLINICAL TRIALS; CONTRACEPTIVES, ORAL, HORMONAL; CYTOKINES; FEMALE; FREE RADICAL SCAVENGERS; GASTROINTESTINAL DISEASES; GROWTH INHIBITORS; HEMATOPOIESIS; HUMANS; MALE; MELATONIN; MIGRAINE DISORDERS; NEOPLASMS; NERVOUS SYSTEM DISEASES; OXIDATIVE STRESS; PINEAL GLAND; RECEPTORS, CELL SURFACE; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, MELATONIN; SHOCK, SEPTIC; SLEEP DISORDERS; VERTEBRATES;

ANIMALIA; AVES; LETHRINIDAE; MAMMALIA; NEGIBACTERIA; VERTEBRATA;

EID: 0031689738     PISSN: 1424862X     EISSN: 14248638     Source Type: Journal    
DOI: 10.1159/000014545     Document Type: Article

References (227)

1. Csaba G, Bodocky M, Fischer J, Acs T: The effect of pinealectomy and thymectomy on the immune capacity of the rat. Experientia 1965;22: 168-175.
2. Vaughan MK, Reiter RJ: Transient hypertrophy of the ventral prostate and coagulating glands and accelerated thymic involution following pi-nealectomy in the mouse. Tex Rep Biol Med 1971;29:579-586.
3. Barath P, Csaba G: Histological changes in the lung, thymus and adrenal one and a half year after pi-nealectomy. Acta Biol Acad Sci Hung 1974;25:123-125.
4. Csaba G, Barath P: Morphological changes of thymus and the thyroid gland after postnatal extirpation of pineal body. Endocrinol Exp 1975; 9:59-67.
5. Maestroni GJM, Pierpaoli W: Pharmacological control of the hormonally modulated immune response; in Ader R (eds): Psychoneuroimmunology. New York, Academic Press, 1981, pp 405-425.
6. Maestroni GJM, Conti A, Pierpaoli W: Role of the pineal gland in immunity. Circadian synthesis and release of melatonin modulates the antibody response and antagonize the immunosuppressive effect of corticosterone. J Neuroimmunol 1986; 13:19-30.
7. Conti A, Haran-Ghera N, Maestroni GJM: Role of pineal melatonin and melatonin - induced - immuno - opioids in murine leukemogenesis. Med Oncol Tumor Pharmacother 1992;9:87-92.
8. Becker J, Veit G, Handgretinger R, Attanasio G, Bruchett G, Trenner I, Niethammer D, Gupta D: Circadian variations in the immunomodulatory role of the pineal gland. Neuroen-docrinol Lett 1988;10:65-80.
9. Champney TH, McMurray DN: Spleen morphology and lympho-proliferative activity in short photoperiod exposed hamsters; in Fras-chini F, Reiter RJ (eds): Role of Melatonin and Pineal Peptides in Neuroimmunomodulation. London, Plenum, 1991, pp 219-225.
10. Del Gobbo V, Libri V, Villani N, Calio R, Nistigo G: Pinealectomy inhibits interleukin-2 production and natural killer activity in mice. Int J Immunopharmacol 1989; 11: 567-577.
11. Palermo MS, Vermeulen M, Giordano M: Modulation of antibody-dependent cellular cytotoxicity by pineal gland; in Maestroni GJM, Conti A, Reiter RJ (eds): Advances in Pineal Research. London, Libbey, 1994, pp 143-147.
12. Haldar C, Haussler D, Gupta D: Response of CFU-GM (colony forming units for granulocytes and macrophages) from intact and pinealecto-mized rat bone marrow to murine recombinant interleukin-3 (rIL-3), recombinant granulocyte-macrophage colony stimulating factor (rGM-CSF) and human recombinant erythropoietin (rEPO). Prog Brain Res 1992;91:323-325.
13. Blask DE: Melatonin in oncology; in Yu H-S, Reiter RJ (eds): Melatonin. Biosynthesis, Physiological Effects, and Clinical Applications. Boca Raton, CRC Press, 1993, pp 447-477.
14. Maestroni GJM: The immunoneu-roendocrine role of melatonin. J Pineal Res 1993;14:1-10.
15. Maestroni GJM, Conti A: Melatonin and the immune-hematopoietic system. Therapeutic and adverse pharmacological correlates. Neu-roimmunomodulation 1996;3:325-332.
16. Giordano M, Palermo MS: Melatonin-induced enhancement of antibody dependent cellular cytotoxicity. J Pineal Res 1991;10:117-121.
17. Caroleo MC, Frasca D, Nistico G, Doria G: Melatonin as immuno-modulator in immunodeficient mice. Immunopharmacology 1992; 23:81-89.
18. Lissoni P, Barni S, Ardizzoia A, Brivio F, Tancini G, Conti A, Maes-troni GJM: Immunological effects of a single evening subcutaneous injection of low-dose interleukin-2 in association with the pineal hormone melatonin in advanced cancer patients. J Biol Regul Homeost Agents 1992;6:132-136.
19. Pioli C, Caroleo MC, Nistico G, Doria G: Melatonin increases antigen presentation and amplifies specific and non specific signals for T-cell proliferation. Int J Immunopharmacol 1993;15:463-469.
20. Morrey MK, McLachlan JA, Serkin CD, Bakouche O: Activation of human monocytes by the pineal neurohormone melatonin. J Immunol 1994;153:2671-2680.
21. Ben-Nathan D, Maestroni GJM, Conti A: Protective effect of melatonin in mice infected with encephalitis viruses. Arch Virol 1995;140s: 223-230.
22. Ben-Nathan D, Maestroni GJM, Conti A: Protective effect of melatonin in viral and bacterial infections (abstract). 2nd Locarno Meeting on Neuroendocrinoimmunolo-gy. Therapeutic Potential of the Pineal Hormone Melatonin. Locarno, May 5-8, 1996.
23. Maestroni GJM: Melatonin as therapeutic agent in experimental endo-toxic shock. J Pineal Res 1996;20: 84-89.
24. Maestroni GJM, Conti A: The pineal neurohormone melatonin stimulates activated CD4+, Thy-1+ cells to release opioid agonist(s) with im-munoenhancing and anti-stress properties. J Neuroimmunol 1990; 28:167-176.
25. Maestroni GJM, Conti A, Pierpaoli W: Role of the pineal gland in immunity. II. Melatonin enhances the antibody response via an opiatergic mechanism. Clin Exp Immunol 1987;68:384-391.
26. Wichmann M, Zellweger R, DeMaso A, Ayala A, Chaudry I: Melatonin administration attenuates depressed immune functions trauma-hemorrhage. J Surg Res 1996;63:256-262.
27. Angeli A, Gatti G, Sartori ML, Del Ponte D, Cerignola R: Effect of exogenous melatonin on human natural killer (NK) cell activity. An approach to the immunomodulatory role of the pineal gland; in Gupta D, Attanasio A, Reiter RJ (eds): The Pineal Gland and Cancer. Tübingen, Müller & Bass, 1988, pp 145-157.
28. Lewinsky A, Zelazowsky P, Sewery-nek E, Zerek-Melen G, Szudlinsky M: Melatonin-induced immunosuppression of human lymphocyte natural killer activity in vitro. J Pineal Res 1989;7:153-164.
29. Maestroni GJM, Conti A: Melatonin in relation to the immune system; in Yu H-S, Reiter RJ (eds): Melatonin. Biosynthesis, Physiological Effects and Clinical Applications. Boca Raton, CRC Press, 1993, pp 290-306.
30. Maestroni GJM, Covacci V, Conti A: Hematopoietic rescue via T-cell-dependent, endogenous GM-CSF by the pineal neurohormone melatonin in tumor bearing mice. Cancer Res 1994;54:2429-2432.
31. Maestroni GJM, Conti A, Lissoni P: Colony-stimulating activity and hematopoietic rescue from cancer chemotherapy compounds are induced by melatonin via endogenous interleukin 4. Cancer Res 1994;54:4740-4743.
32. Hansson I, Holmdahl R, Mattsson R: The pineal hormone melatonin exaggerates development of collagen-induced arthritis in mice. J Neuroimmunol 1992;39:23-31.
33. Colombo LL, Chen G-J, Lopez MC, Watson RR: Melatonin induced increase in gamma-interferon production by murine splenocytes. Immunol Lett 1992;33:123-126.
34. Hofbauer LC, Heufelder AE: Endocrinology meets immunology: T lymphocytes as novel targets for melatonin. Eur J Endocrinol 1996; 134:424-425.
35. Guerrero J-M, Garcia-Maurino S, Gil-Haba M, Rafii-El-Idrissi M, Pozo D, Garcia-Perganeda A, Calvo JR: Mechanisms of action on the human immune system: Membrane receptors versus nuclear receptors; in Maestroni GJM, Conti A, Reiter RJ (eds): Therapeutic Potential of the Pineal Hormone Melatonin. Basel, Karger, 1996, pp 43-52.
36. Maestroni GJM, Conti A: Antistress role of the melatonin-immu-no-opioid network. Evidence for a physiological mechanism involving T cell-derived, immunoreactive P-endorphin and metenkephalin binding to thymic opioid receptors. Int J Neurosci 1991;61:289-298.
37. Maestroni GJM, Conti A: Beta-endorphin and dynorphin mimic the circadian immunoenhancing and anti-stress effects of melatonin. Int J Immunopharmacol 1989; 11:333-340.
38. Maestroni GJM, Hertens E, Galli P, Conti A, Pedrinis E: Melatonin-induced T-helper cell hematopoietic cytokines resembling both interleukin-4 and dynorphin. Pineal Res 1996;21:131-139.
39. Young MRI, Young ME, Kim K: Regulation of tumor-induced my-elopoiesis and the associated immune suppressor cells in mice bearing metastatic Lewis lung carcinoma by prostaglandin E2. Cancer Res 1988;48:6826-6831.
40. Conti A, Maestroni GJM: The clinical neuroimmunotherapeutic role of melatonin in oncology. J Pineal Res 1995;19:103-110.
41. Neri B, Fiorelli C, Moroni F, Nicita G, Paoletti MC, Ponchietti R, Raugei A, Santoni G, Trippitelli A, Grechi G: Modulation of human lym-phoblastoid interferon activity by melatonin in metastatic renal cell carcinoma. A phase II study. Cancer 1994;73: 3015-3019.
42. Lissoni P, Brivio F, Brivio O, Fumagalli L, Gramazio F, Rossi M, Emanuelli G, Alderi G, Lavorato F: Immune effects of preoperative immunotherapy with high-dose subcutaneous interleukin-2 versus neuroimmunotherapy with low-dose interleukin-2 plus the neurohormone melatonin in gastrointestinal tract tumor patients. J Biol Regul Ho-meost Agents 1995;9:31-33.
43. Maestroni GJM: Kappa-opioid receptors in marrow stroma mediate the hematopoietic effects of melatonin-induced opioid cytokines. Ann NY Acad Sci, in press.
44. Konakchieva R, Kyurkchiev S, Ke-hayov I, Taushanova P, Kanchev LA: Selective effect of methoxyin-doles on the lymphocyte proliferation and melatonin binding to activated human lymphoid cells. J Neu-roimmunol 1995;63:125-132.
45. Withyachumnarnkul B, Nonaka KO, Santana C, Attia AM, Reiter RJ: Interferon-gamma modulates melatonin production in rat pineal gland in organ culture. J Interferon Res 1990;10:403-411.
46. Blask DE, Hill SM: Melatonin and cancer: Basic and clinical aspects; in Miles A, Philbrick DRS, Thompson C (eds): Melatonin. Clinical Perspectives. Oxford, Oxford University Press, 1988, pp 128-173.
47. Blask DE: Systemic, cellular and molecular aspects of melatonin action on experimental breast carcinogenesis; in Stevens RG, Wilson BW, Anderson LE (eds): The Melatonin Hypothesis. Breast Cancer and the Use of Electric Power. Columbus, Battelle Press, 1997, pp 189-230.
48. Blask DE: The melatonin rhythm in cancer patients; in Shafi M (ed): Melatonin in Psychiatric and Neoplastic Disorders. Washington, Am Psychiatric Press 1997, pp 257-275.
49. Bartsch C, Bartsch H, Lippert TH: Rationales to consider the use of melatonin as a chrono-oncothera-peutic drug. In Vivo 1995;9:305-310.
50. Maestroni GJM, Conti A: Melatonin in human breast cancer tissue: Association with nuclear grade and estrogen receptor status. Lab Invest 1996;75:557-561.
51. Bartsch C, Kvetnoy I, Kvetnaia T, Bartsch H, Molotkov A, Franz H, Raikhlin N, Mecke D: Nocturnal urinary 6-sulfatoxymelatonin and proliferating cell nuclear antigen-immunopositive tumor cells show strong positive correlations in patients with gastrointestinal and lung cancer. J Pineal Res 1997;23:90-96.
52. Panzer A, Viljoen M: The validity of melatonin as an oncostatic agent. J Pineal Res 1997;22:184-202.
53. Lewy AJ, Ahmed S, Jackson JM, Sack RL: Melatonin shifts human circadian rhythms according to a phase-response curve. Chronobiol Int 1992;9:380-392.
54. Dollins AB, Lynch HJ, Wurtman RJ, Deng MH, Kischka KU, Gleason RE, Lieberman HR: Effect of pharmacological daytime doses of melatonin on human mood and performance. Psychopharmacology 1993;112:490-496.
55. Dollins AB, Zhdanova IV, Wurt-man RJ, Lynch HJ, Deng MH: Effect of inducing nocturnal serum melatonin concentrations in daytime on sleep, mood, body temperature, and performance. Proc Natl Acad Sci USA 1994;91:1824-1828.
56. Reppert SM, Godson C, Mahle CD, Weaver DR, Slaugenhaupt SA, Gu-sella JF: Molecular characterization of a second melatonin receptor expressed in human retina and brain: The Mellb melatonin receptor. Proc Natl Acad Sci USA 1995;92:8734-8738.
57. Reppert SM, Weaver DR, Ebisawa T: Cloning and characterization of a mammalian melatonin receptor that mediates reproductive and circadian responses. Neuron 1994;13: 1177-1185.
58. Reppert SM, Weaver DR, Cassone VM, Godson C, Kolakowski LF Jr: Melatonin receptors are for the birds: Molecular analysis of two receptor subtypes differentially expressed in chick brain. Neuron 1995;15:1003-1015.
59. Liu F, Yuan H, Sugamori KS, Ha-madanizadeh A, Lee FJ, Pang SF, Brown GM, Pristupa ZB, Niznik HB: Molecular and functional characterization of a partial cDNA encoding a novel chicken brain melatonin receptor. FEBS Lett 1995;374: 273-278.
60. Brown GM: Melatonin in psychiatric and sleep disorders: Therapeutic implications. CNS Drugs 1995;3: 209-226.
61. Borbely AA: A two process model of sleep regulation. Hum Neurobiol 1982;1:195-204.
62. Achermann P, Dijk DJ, Brunner DP, Borbely AA: A model of human sleep homeostasis based on EEG slow-wave activity: Quantitative comparison of data and simulations. Brain Res Bull 1993;31:97-113.
63. Dijk DJ, Czeisler CA: Contribution of the circadian pacemaker and the sleep homeostat to sleep propensity, sleep structure, electroencephalo-graphic slow waves, and sleep spindle activity in humans. J Neurosci 1995; 15(5 Pt 1):3526-3538.
64. Arendt J, Aldhous M, Marks V: Alleviation of jet lag by melatonin: Preliminary results of controlled double blind trial. Br Med J 1986; 292:1170.
65. Arendt J, Aldhous M: Further evaluation of the treatment of jet-lag by melatonin: A double-blind crossover study. Annu Rev Chronopharmacol 1988;5:53-55.
66. Petrie K, Conaglen JV, Thompson L, Chamberlain K: Effect of melatonin on jet lag after long haul flights. BMJ 1989;298:705-707.
67. Petrie K, Dawson AG, Thompson L, Brook R: A double-blind trial of melatonin as a treatment for jet lag in international cabin crew. Biol Psychiatry 1993;33:526-530.
68. Claustrat B, Brun J, David M, Sas-solas G, Chazot G: Melatonin and jet lag: Confirmatory result using a simplified protocol. Biol Psychiatry 1992;32:705-711.
69. Comperatore CA, Lieberman HR, Kirby AW, Adams B, Crowley JS: Melatonin efficacy in aviation missions requiring rapid deployment and night operations. Aviat Space Environ Med 1996;67:520-524.
70. Dahlitz M, Alvarez B, Vignau J, English J, Arendt J, Parkes JD: Delayed sleep phase syndrome response to melatonin. Lancet 1991; 337:1121-1124.
71. Tzischinsky O, Dagan Y, Lavie P: The effects of melatonin on the timing of sleep in patients with delayed sleep phase syndrome; in Touitou Y, Arendt J, Pevet P (eds): Melatonin and the Pineal Gland: From Basic Science to Clinical Application. Amsterdam, Excerpta Medica, 1993, pp 351-354.
72. Oldani A, Ferini-Strambi L, Zucconi M, Stankov B, Fraschini F, Smirne S: Melatonin and delayed sleep phase syndrome: Ambulatory polygraphic evaluation. Neuroreport 1994;6:132-134.
73. Lapierre O, Dumont M: Melatonin treatment of a non-24-hour sleep-wake cycle in a blind retarded child. Biol Psychiatry 1995;38:119-122.
74. Folkard S, Arendt J, Aldhous M, Kennett H: Melatonin stabilises sleep onset time in a blind man without entrainment of cortisol or temperature rhythms. Neurosci Lett 1990;113:193-198.
75. Arendt J, Aldhous M, Wright J: Synchronisation of a disturbed sleep-wake cycle in a blind man by melatonin treatment (letter). Lancet 1988;Vol i:772-773.
76. Sack RL, Lewy AJ, Blood ML, Stevenson J, Keith LD: Melatonin administration to blind people: Phase advances and entrainment. J Biol Rhythms 1991;6:249-261.
77. Palm L, Blennow G, Wetterberg L: Correction of non-24-hour sleep/ wake cycle by melatonin in a blind retarded boy. Ann Neurol 1991;29: 336-339.
78. Jan JE, Espezel H, Appleton RE: The treatment of sleep disorders with melatonin. Dev Med Child Neurol 1994;36:97-107.
79. Jan JE, O’Donnell ME: Use of melatonin in the treatment of paediatric sleep disorders. J Pineal Res 1996; 21:193-199.
80. Jan JE, Abroms IF, Freeman RD, Brown GM, Espezel H, Connolly MB: Rapid cycling in severely multidisabled children: A form of bipolar affective disorder? Pediatr Neurol 1994;10:34-39.
81. Horne JA, Donlon J, Arendt J: Green light attenuates melatonin output and sleepiness during sleep deprivation. Sleep 1991; 14:233-240.
82. Touitou Y, Fevre M, Bogdan A, Reinberg A, DePrins J, Beck H, Touitou C: Patterns of plasma melatonin with ageing and mental condition: Stability of nyctohemeral rhythms and differences in seasonal variations. Acta Endocrinol 1984; 106:145-151.
83. Iguchi H, Kato K-I, Ibayashi H: Age-dependent reduction in serum melatonin concentrations in healthy human subjects. J Clin Endocrinol Metab 1982;55:27-29.
84. Sharma M, Palacios-Bois J, Schwartz G, Iskandar H, Thakur M, Quirion R, Nair NP: Circadian rhythms of melatonin and cortisol in aging. Biol Psychiatry 1989;25:305-319.
85. Murialdo G, Costelli P, Fonzi S, Parodi C, Torre F, Cenacchi T, Polleri A: Circadian secretion of melatonin and thyrotropin in hospitalized aged patients. Aging 1993;5:39-46.
86. van Coevorden A, Mockel J, Laurent E, Kerkhofs M, L’Hermite-Ba-leriaux M, Decoster C, Neve P, Van Cauter E: Neuroendocrine rhythms and sleep in aging men. Am J Physiol 1991;260:E651-E661.
87. Ferrari E, Magri F, Locatelli M, Balza G, Nescis T, Battegazzore C, Cuz-zoni G, Fioravanti M, Solerte SB: Chrono-neuroendocrine markers of the aging brain. Aging 1996;8:320-327.
88. Lam RW, Berkowitz AL, Berga SL, Clark CM, Kripke DF, Gillin JC: Melatonin suppression in bipolar and unipolar mood disorders. Psychiatry Res 1990;33:129-134.
89. Kennedy SH, Brown GM, Garfinkel PE, McVey G, Parienti V: Sulpha-toxy melatonin: An index of depression in anorexia nervosa and bulimia nervosa. Psychiatry Res 1990;32: 221-227.
90. Frazer A, Brown R, Kocsis J, Caroff S, Amsterdam J, Winokur A, Sweeney J, Stokes P: Patterns of melatonin rhythms in depression. J Neural Transm Suppl 1986;21:269-290.
91. Souetre E, Salvati E, Belugou JL, Pringuey D, Candito M, Krebs B, Ardisson JL, Darcourt G: Circadian rhythms in depression and recovery: Evidence for blunted amplitude as the main chronobiological abnormality. Psychiatry Res 1989;28: 263-278.
92. Kennedy SH, Garfinkel PE, Parienti V, Costa D, Brown GM: Changes in melatonin levels but not cortisol levels are associated with depression in patients with eating disorders. Arch Gen Psychiatry 1989;46:73-78.
93. Beck-Friis J, Ljunggren JG, Thoren M, von Rosen D, Kjellman BF, Wetterberg L: Melatonin, cortisol and ACTH in patients with major depressive disorder and healthy humans with special reference to the outcome of the dexamethasone suppression test. Psychoneuroendocrinology 1985;10:173-186.
94. Claustrat B, Chazot G, Brun J, Jordan D, Sassolas G: A chronobiologi-cal study of melatonin and cortisol secretion in depressed subjects: Plasma melatonin, a biochemical marker in major depression. Biol Psychiatry 1984;19:1215-1228.
95. McIntyre IM, Judd FK, Norman TR, Burrows GD: Plasma melatonin concentrations in depression. Aust N Z J Psychiatry 1986;20:381-383.
96. Brismar K, Hylander B, Eliasson K, Rossner S, Wetterberg L: Melatonin secretion related to side-effects of beta-blockers from the central nervous system. Acta Med Scand 1988;223:525-530.
97. Arendt J: Melatonin and the mammalian pineal gland. London, Chapman & Hall, 1995, pp 202.
98. Dawson D, Encel N: Melatonin and sleep in humans. J Pineal Res 1993;15:1-12.
99. Haimov I, Laudon M, Zisapel N, Souroujon M, Nof D, Shlitner A, Herer P, Tzischinsky O, Lavie P: Sleep disorders and melatonin rhythms in elderly people. BMJ 1994;309:167.
100. Lushington K, Lack L, Dawson D: Melatonin production in good and poor elderly sleepers. Sleep 1995; 24A:168.
101. Hajak G, Rodenbeck A, Staedt J, Bandelow B, Huether G, Ruther E: Nocturnal plasma melatonin levels in patients with primary insomnia. J Pineal Res 1996;19:116-122.
102. Waldhauser F, Weiszenbacher G, Tatzer E, Geisinger B, Waldhauser M, Schemper M, Frisch H: Alternations in the nocturnal serum melatonin levels in humans with growth and aging. J Clin Endocrinol Metab 1988;66:648-652.
103. Brugger P, Markti W, Harold M: Impaired nocturnal secretion of melatonin in coronary heart disease. Lancet 1995;345:1408.
104. Fiorina P, Lattuada G, Ponari O, Silvestrini C, Dal’Aglio F: Impaired nocturnal melatonin excretion and changes in immunological status in ischemic stroke patients. Lancet 1997;347:692-693.
105. Kabuto M, Namura I, Saitoh Y: Enhancement of plasma melatonin could be suppressed by benzodiazepines in humans. Endocrinol Jpn 1986;33:405-414.
106. Haimov I, Lavie P, Laudon M, Herer P, Vigder C, Zisapel N: Melatonin replacement therapy of elderly insomniacs. Sleep 1995; 18: 598-603.
107. Garfinkel D, Laudon M, Zisapel N: Improvement of sleep quality in elderly people by controlled release melatonin. Lancet 1995;346:541-544.
108. Garfinkel D, Laudon M, Zisapel N: Improvement of sleep quality by controlled-release melatonin in benzodiazepine-treated elderly insomniacs. Arch Gerontol Geriat 1997;4:223-231.
109. Viswanathan M, Laitinen JT, Saavedra JM: Expression of melatonin receptors in arteries involved in thermoregulation. Proc Natl Acad Sci USA 1990;87:6200-6203.
110. Evans BK, Mason R, Wilson VG: Evidence for direct vasoconstriction of melatonin in ‘pressurized’ segments of isolated caudal artery from juvenile rats. Naunyn Schmiedebergs Arch Pharmacol 1992;346:362-365.
111. Krause DN, Barrios VE, Duckles SP: Melatonin receptors mediate potentiation of contractile responses to adrenergic nerve stimulation in rat caudal artery. Eur J Pharmacol 1995;276:207-213.
112. Geary GG, Krause DN, Duckles SP: Melatonin directly constricts rat cerebral arteries through modulation of potassium channels. Am J Physiol 1997;273:H1530-H1536.
113. Stankov B, Capsoni S, Lucini V, Fautek J, Gatti S, Gridelli B, Biella G, Cozzi B, Fraschini F: Autoradiographic localization of putative melatonin receptors in the brains of two old world primates: Cerco-pithecus aethiops and Papio ursin-us. Neuroscience 1993;52:459-468.
114. Rivkees SA, Reppert SM: Appearance of melatonin receptors during embryonic life in Siberian hamster (Phodopus sungorus). Brain Res 1991;568:345-349.
115. Laitinen JT, Viswanathan M, Vak-kuri O, Saavedra JM: Differential regulation of the rat melatonin receptors: Selective age-associated decline and lack of melatonin-induced changes. Endocrinology 1992;130:2139-2144.
116. Viswanathan M, Laitinen JT, Saavedra JM: Differential expression of melatonin receptors in spontaneously hypertensive rats. Neuroendocrinology 1992;56: 864-870.
117. Seltzer A, Viswanathan M, Saavedra JM: Melatonin-binding sites in brain and caudal arteries of the female rat during the estrous cycle and after estrogen administration. Endocrinology 1992; 130:1896-1902.
118. Viswanathan M, Sclabert E, Dela-grange P, Guardiola-Lemaitre B, Saavedra JM: Melatonin receptors mediate contraction of a rat cerebral artery. Neuroreport 1997;8: 3847-3849.
119. Nelson M, Quayle JM: Physiological roles and properties of potassium channels in arterial smooth muscle. Am J Physiol 1995;268: C799-C822.
120. Strassmann RJ, Qualls CR, Li-sansky EJ, Peake GT: Elevated rectal temperature produced by all night bright light is reversed by melatonin infusion in men. J Appl Physiol 1991;71:2178-2182.
121. Cagnacci A, Elliot JA, Yen SSC: Melatonin: A major regulator of the circadian rhythm of core temperature in humans. J Clin Endocrinol Metab 1992;75:447-452.
122. Cagnacci AR, Soldani R, Yen SSC: Hypothermic effect of melatonin and nocturnal core body temperature decline are reduced in aged women. J Appl Physiol 1995;78: 314-317.
123. Krauchi K, Cajochen C, Wirz-Jus-tice A: A relationship between heat loss and sleepiness: Effects of postural change and melatonin administration. J Appl Physiol 1997; 83:134-139.
124. Krauchi K, Cajochen C, Danilen-ko V, Wirz-Justice A: The hypothermic effect of late evening melatonin does not block the phase delay induced by concurrent bright light in human subjects. Neurosci Lett 1997;232:57-61.
125. Chazot G, Claustrat B, Broussolle E, Lapras C: Headache and depression: Recurrent symptoms in adult pinealectomized patients; in Nappi G (ed): Headache and Depression. New York, Raven Press, 1991, pp 299-303.
126. Claustrat B, Loisy C, Brun J, Beor-chia S, Arnaud JL, Chazot G: Nocturnal plasma levels in migraine: A preliminary report. Haedache 1989;29:242-245.
127. Claustrat B, Burn J, Geoffriau M, Ziadan R, Mallo C, Chazot G: Nocturnal plasma melatonin profile and melatonin kinetics during the infusion in status migrainosus. Cephalalgia 1997;17:511-517.
128. Brun J, Claustrat B, Saddier P, Chazot G: Nocturnal melatonin excretion is decreased in patients with migraine without aura attacks associated with menses. Cephalalgia 1995;15:136-139.
129. Murialdo G, Fonzi S, Costellani P, Solinas GP, Parodi C, Marabini S, Fanciullacci M, Pollieri A: Urinary melatonin excretion throughout the ovarian cycle in menstrually related migraine. Cephalalgia 1994; 14:205-209.
130. Toglia JU: Is migraine due to a deficiency in pineal melatonin? Ital J Neurol Sci 1986;7:319-323.
131. De la Fuente J: MRI-induced headache. Psychiatry Res 1986;37: 319-323.
132. Karpanne H, Airaksin M, Sarki-mals I: Effects in rats of locomotor activity and blood pressure during the various lighting schedule. Ann Med Exp Biol Fen 1973;51:93-103.
133. Birau N, Peterssen U, Gottschalk J: Hypotensive effect of melatonin in essential hypertension. IRCS Med Sci 1981;9:906.
134. Satake N, Oe H, Sawada T, Shiba-ta S: The mode of vasorelaxing action of melatonin in rabbit aorta. Gen Pharmacol 1991;22:219-221.
135. Shibata S, Satake N, Takagi T, Usui H: Vasorelaxing action of melatonin in rabbit basilar artery. Gen Pharmacol 1991;20:677-680.
136. Capsoni S, Stankov BM, Fraschini F: Reduction of regional cerebral blood flow by melatonin in young rats. Neuroreport 1995;6:1346-1348.
137. Bittman EL, Karsch FJ: Nightly duration of pineal melatonin secretion determines the reproductive response to inhibitory day length in the ewe. Biol Reprod 1984;30: 585-593.
138. Reiter RJ: The melatonin rhythm: Both a clock and a calendar. Ex-perientia 1993;49:654-664.
139. Pang SF, Pang CS, Poon AMS, Shiu SWY, Song Y, Lee PPN, Zhao Y, Liu ZM: Pineal melatonin and its receptors in humans; in Tang PL, Pang SF, Reiter RJ (eds): Melatonin: A Universal Periodic Signal with Diverse Actions. Front Horm Res. Basel, Karger, 1996, vol 21, pp 133-146.
140. Ebisawa T, Karne S, Lerner MR, Reppert SM: Expression cloning of a high-affinity melatonin receptor from Xenopus dermal melano-phores. Proc Natl Acad Sci USA 1994;91:6133-6137.
141. Voorsdouw BCG, Euser R, Ver-donk RER, Alberda BTH, De Jong RH, Drogendijk AATC, Fauser BCJM, Cohen M: Melatonin and melatonin-progestin combinations alter pituitary-ovarian function in women and can inhibit ovulation. J Clin Endocrinol Metab 1992;74: 108-117.
142. Shiu SYW, Pang SF: A molecular perspective of the genetic relationships of G-protein coupled melatonin receptor subtypes. J Pineal Res 1996;20:198-204.
143. Vakkuri O, Lamsa E, Rahkamaa E, Routsalainen H, Leppaluoto J: Iodinated melatonin: Preparation and characterization of the molecular structure by mass and 1H NMR spectroscopy. Anal Biochem 1984;142:284-298.
144. Fraschini F, Mess B, Martini L: Pineal gland, melatonin and the control of luteinizing hormone secretion. Endocrinology 1968;82: 919-924.
145. Glass DJ, Knotts LK: A brain site for the antigonadal action of melatonin in the white-footed mouse (Peromyscus leucopus): Involvement of the immunoreactive GnRH neuronal system. Neuroendocrinology 1987;40:48-55.
146. Kamberi IA, Mical RS, Porter JC: Effect of anterior pituitary perfusion and intraventricular injection of catecholamines and indoleamines on LH release. Endocrinology 1970;87:1-12.
147. Martin JE, Klein DC: Melatonin inhibition of the neonatal pituitary response to luteinizing hormonereleasing factor. Science 1976; 191: 301-302.
148. Masson-Pevet M, Gauer F, Recio J: Melatonin receptors, pars tuber-alis and photoperiodic response. Front Horm Res 1996;21:84-89.
149. Vanecek J, Pavlik A, Illnerova H: Hypothalamic melatonin receptor sites revealed by autoradiography. Brain Res 1987;435:359-362.
150. Weaver DR, Reppert SM: The Mel1a melatonin receptor gene is expressed in human suprachias-matic nuclei. Neuroreport 1996;8: 109-112.
151. 125I]iodomela-tonin binding sites in the testes and ovaries of the chicken (Gallus domesticus). J Endocrinol 1992; 133:5-11.
152. 125I]iodomelatonin binding sites in duck gonads. J Pineal Res 1994;17:39-47.
153. 125I]iodomelatonin binding sites in quail testes at midlight and middark. Neurosci Lett 1992; 146:195-198.
154. 125]iodomelatonin binding in the testis and brain of quail. Biological Signals 1993;2:146-154.
155. 125I]Iodo-melatonin binding sites in the testis and ovary: Putative melatonin receptors in the gonads. Biol Signals 1994;3:71-84.
156. Yie SM, Niles LP, YoungLai EV: Melatonin receptors on human granulosa cell membranes. J Clin Endocrinol Metab 1995;80:1747-1749.
157. 125I]iodomelatonin binding sites in the rat epididymis. J Pineal Res 1994;17:195-201.
158. Shiu SYW, Yu ZH, Chow PH, Pang SF: Putative melatonin receptors in the male reproductive tissues. Front Horm Res 1996;21: 90-100.
159. 125I]iodomelato-nin binding in rat epididymis. Life Sci 1996;59:1165-1174.
160. Shiu SYW, Li L, Wong JTY, Pang SF: Biology of G protein-coupled melatonin receptors in the epididymis and prostate of mammals. Chin Med J, in press.
161. Carneiro RCG, Cipolla-Neto J, Markus RP: Diurnal variation of the rat vas deferens contraction induced by stimulation of presynaptic nicotinic receptors and pineal function. J Pharmacol Exp Ther 1991;259:614-619.
162. Carneiro RCG, Markus RP, Du-bocovich ML: Presynaptic modulation by melatonin of the nicotine-induced calcium-dependent release of norepinephrine from rat vas deferens. Biol Signals 1993;2: 199-206.
163. 125I]Iodomela-tonin binding sites in the rat vas deferens. Biol Signals 1993;2:194-198.
164. Laudon M, Gilad E, Matzkin H, Braf Z, Zisapel N: Putative melatonin receptors in benign human prostate tissue. J Clin Endocrinol Metab 1996;81:1336-1342.
165. Blask DE, Lemus-Wilson AM, Wilson ST: Breast cancer: A model system for studying the neuroendocrine role of pineal melatonin in oncology. Biochem Soc Trans 1992;20:309-311.
166. 125I]Iodomelatonin binding sites in murine mammary tissue. Biol Signals 1994;3:85-90.
167. 125I]iodomelatonin binding sites in murine mammary tissue. J Pineal Res 1994; 16:1017.
168. Song Y, Chan CW, Brown GM, Pang SF, Silverman M: Studies of the renal action of melatonin: Evidence that the effects are mediated by 37 kDa receptors of the MelIa subtype localized primarily to the basolateral membrane of the proximal tubule. FASEB J 1997; 11:93100.
169. Puig-Domingo M, Rajmil O, Tor-tosa F, de Leiva A: Role of the pineal hormone melatonin in patients with hypergonadotropic and hypogonadotropic hypogonadisms; in Tang PL, Pang SF, Reiter RJ (eds): Melatonin: A Universal Photoperiodic Signal with Diverse Actions. Front Horm Res. Basel, Karger, 1996, vol 21, pp 186-198.
170. Reiter RJ, Tang L, Garcia JJ, Mu-noz-Hoyos A: Pharmacological actions of melatonin in oxygen radical pathophysiology. Life Sci 1997; 60:2255-2271.
171. Reiter RJ, Carneiro RC, Oh CS: Melatonin in relation to cellular antioxidative defense mechanisms. Horm Metab Res 1997;29: 363-372.
172. Tan DX, Chen LD, Poeggeler B, Manchester LC, Reiter RJ: Melatonin: A potent endogenous, hydroxyl radical scavenger. Endocr J 1993;1:57-60.
173. Matuszak Z, Reszka KJ, Chignell CF: Reaction of melatonin and related indoles with hydroxyl radicals: EPR and spin trapping investigations. Free Radic Biol Med 1997;23:367-372.
174. Reiter RJ: Antioxidant actions of melatonin. Adv Pharmacol 1997; 38:103-117.
175. Garcia JJ, Reiter RJ, Guerrero JM, Escames G, Yu BP, Oh CS, Munoz-Hoyos A: Melatonin prevents changes in microsomal membrane fluidity during induced lipid peroxidation. FEBS Lett 1997;408:297-300.
176. Susa N, Uemo S, Furukawa Y, Ueda J, Sugiyama M: Potent protective effect of melatonin on chro-muim (VI) induced DNA single strand breaks, cytotoxicity, and lipid peroxidation in primary cultures of rat hepatocytes. Toxicol Appl Pharmacol 1997; 144:377-384.
177. Tang L, Reiter RJ, Li ZR, Ortiz GG, Yu BP, Garcia JJ: Melatonin reduces the increase in 8-hydroxy-deoxyguanosine levels in the brain and liver of kainic acid-treated rats. Mol Cell Biochem, in press.
178. Yamamoto HA, Tang HW: Melatonin attenuates L-cysteine-in-duced seizures and lipid peroxidation in the brain of mice. J Pineal Res 1996;21:108-113.
179. Hardeland R, Reiter RJ, Poeggeler B, Tan DX: The significance of the metabolism of the neurohormone melatonin: Antioxidant protection and formation of bioactive substances. Neurosci Biobehav Res 1993;17:347-357.
180. Carlberg C, Weisenberg I: The orphan receptor family RZR/ROR, melatonin and 5-lipoxygenase: An unexpected relationship. J Pineal Res 1995;18:171-178.
181. Pozo D, Reiter RJ, Calvo JR, Guerrero JM: Inhibition of cerebellar nitric oxide synthase and cyclic AMP production by melatonin via complex formation with calmodulin. J Cell Biochem 1997; 65:430-442.
182. Uz T, Guisti P, Franceschini D, Kharlamov A, Manev H: Protective effect of melatonin against hippocampal DNA damage induced by intraperitoneal administration of kainate to rats. Neuroscience 1996;73:631-636.
183. Pappolla MA, Sos M, Omar RA, Bick RJ, Hickson-Bick DLM, Reiter RJ, Efthimiopoulos S, Ro-bakis NK: Melatonin prevents death of neuroblastoma cells exposed to the Alzheimer amyloid peptide. J Neurosci 1997; 17: 1683-1690.
184. Acuna-Castroviejo D, Coto-Montes A, Monti MG, Ortiz GG, Reiter RJ: Melatonin is protective against MPTP-induced striatal and hippocampal lesions. Life Sci 1997;60:PL23-PL29.
185. Guerrero JM, Reiter RJ, Ortiz GG, Pablos MI, Sewerynek E, Chuang JI: Melatonin prevents increases in neural nitric oxide and cyclic GMP production after transient brain ischemia and reperfusion in the Mongolian gerbil (Meri-ones unguiculatus). J Pineal Res 1997;23:24-31.
186. Princ FG, Juknat AA, Maxit AG, Cordalda C, Battle A: Melatonin’s antioxidant protection against β-aminolevulinic acid-induced oxidative damage in the cerebellum. J Pineal Res 1997;23:40-46.
187. Sewerynek E, Melchiorri D, Chen LD, Reiter RJ: Melatonin reduces basal and bacterial lipopolysaccha-ride-induced lipid peroxidation in vitro. Free Radic Biol Med 1995; 19:903-909.
188. Pablos MI, Reiter RJ, Chuang JI, Ortiz GG, Guerrero JM, Sewery-nek E, Agapito MT, Melchiorri D, Lawrence R, Deneke SM: Acutely administered melatonin reduces oxidative damage in lung and brain induced by hyperbaric oxygen. J Appl Physiol 1997;83:354-358.
189. Brzozowski T, Konturek PC, Kon-turek SJ, Pojdo R, Billanski W, Brzozowsku I, Stachura J, Hahn EG: The role of melatonin and L-tryptophan in prevention of acute gastric lesions induced by stress, ethanol, ischemia and aspirin. J Pineal Res 1997;23:79-89.
190. Cuzzocrea S, Zingarelli B, Gilad E, Hake P, Salzman AL, Szabo C: Protective effect of melatonin in carrageen-induced models of local inflammation: Relationship to its inhibitory effect on nitric oxide production and its peroxynitrite scavenging activity. J Pineal Res 1997;23:106-116.
191. Huether G: The contribution of extrapineal sites of melatonin synthesis to circulating melatonin levels in higher vertebrates. Experien-tia 1993;49:665-670.
192. Huether G, Hajak G, Reimer A, Poeggeler R, Blomer M, Rodenbeck A, Ruther E: The metabolic fate of infused L-tryptophan in men: Possible clinical implications of the accumulation of circulating tryptophan and tryptophan metabolites. Psychopharmacology 1992; 106:422-432.
193. Huether G, Poegeler B, Reimer R, George A: Effect of tryptophan administration on circulating melatonin levels in chicks and rats: Evidence for stimulation of melatonin synthesis and release in the gastrointestinal tract. Life Sci 1992; 51:945-953.
194. Yaga K, Reiter RJ, Richardson BA: Tryptophan loading increases daytime serum melatonin in intact and pinealectomized rats. Life Sci 1993;52:1231-1238.
195. Chow PH, Lee PN, Poon AMS, Shiu SYW, Pang SF: The gastrointestinal system: A site of melatonin paracrine action; in Tang PL, Pang SF, Reiter RJ (eds): Melatonin: A Universal Photoperiodic Signal with Diverse Actions. Front Horm Res. Basel, Karger, 1996, vol 21, pp 123-132.
196. Bubenik GA: Phylogeny, Ontogeny and Function of Gastrointestinal Melatonin. 5th Can Pineal Melatonin Symp, Guelph, July 13-15, 1997.
197. Bubenik GA: The effect of serotonin, N-acetylserotonin and melatonin on spontaneous contractions of isolated rat intestine. J Pineal Res 1986;3:41-54.
198. Harlow HJ, Weekly BL: Effect of melatonin on the force of spontaneous contractions of in vitro rat small and large intestine. J Pineal Res 1986;3:277-284.
199. Bubenik GA, Pang SF: The role of serotonin and melatonin in the gastrointestinal physiology: Ontogeny, regulation of food intake and mutual 5-HT, melatonin feedbacks. J Pineal Res 1994; 16:9199.
200. Legris GJ, Will PC, Hopfer U: Inhibition of amiloride-sensitive sodium conductance by indolealkylamines. Proc Natl Acad Sci USA 1982;79:2046-2050.
201. Pentney P, Bubenik GA: Melatonin reduces the severity of dextran-induced colitis in mice. J Pineal Res 1995;19:31-39.
202. Zerek-Melen G, Lewinski A, Kulak J: The opposite effect of high and low doses of melatonin upon mitotic activity of the mouse intestinal epithelium. Endokrynol Pol 1987; 38:317-323.
203. Bubenik GA, Ball RO, Pang SF: The effect of food deprivation on brain and gastrointestinal tissue levels of tryptophan, serotonin, 5-hydroxyindoleacetic acid, and melatonin. J Pineal Res 1992;12: 7-16.
204. Huether G: Melatonin synthesis in the gastrointestinal tract and the impact of nutritional factors on circulating melatonin, Ann NY Acad Sci 1994;719:146-158.
205. Raikhlin NT, Kvetnoy IM, Kada-gidze ZG, Sokolov V: Immuno-morphological studies on synthesis of melatonin in enterochromaffin cells. Acta Histochem Cytochem 1978;11:75-77.
206. Bubenik GA, Brown GM, Grota LJ: Immunohistological localization of melatonin in the rat digestive tract. Experientia 1977;33: 662-663.
207. Bubenik GA: Localization of melatonin in the digestive tract of the rat. Effect of maturation, diurnal variation, melatonin treatment and pinealectomy. Horm Res 1980;12:313-323.
208. Quastel MR, Rahamimoff R: Effect of melatonin on spontaneous contraction and response to 5-hy-droxytryptamine of rat isolated duodenum. Br J Pharmacol 1965; 24:455-461.
209. Fioretti MC, Barzi F, Martini L: Affinity of melatonin for serotonin receptors in the isolated rat stomach (in Italian). Riv Farmacol Ter-ap 1972;3:383-391.
210. Fioretti MC, Menconi E, Riccardi C: Mechanisms of the in vitro 5-hydroxytryptamine (5-HT) antagonism exerted by pineal indole derivatives (in Italian). Riv Farmacol Ter 1974;5:43-49.
211. Tache Y, Stevens RL, Ishikawa T: Central nervous system action of TRH influences gastrointestinal function and ulceration. Ann NY Acad Sci 1989;553:269-285.
212. Wong SH, Cho CH, Ogle CW: The role of ethanol-induced gastric glandular damage in rats. Digestion 1990;45:52-60.
213. Ayles HL, Ball RO, Friendship RM, Bubenik GA: The effect of graded levels of melatonin on performance and gastric ulcers in pigs. Can J Anim Sci 1996;76:607-611.
214. Cho HC, Pang SF, Chen BW, Pfeifer CJ: Modulating action of melatonin on serotonin-induced aggravation of ethanol ulceration and changes of mucosal blood flow in rat stomach. J Pineal Res 1989; 6:89-97.
215. Khan R, Daya S, Potgieter B: Evidence for the modulation of the stress response by the pineal gland. Experientia 1990;46:860-862.
216. Konturek PC, Konturek SJ, Brzo-zowski T, Dembinski A, Zembala M, Mytar B, Hahn EG: Gastro-protective activity of melatonin and its precursor, L-tryptophan, against stress-induced and ischemia-induced lesions is mediated by scavenge of oxygen radicals. Scand J Gastroenterol 1997;32: 433-438.
217. Konturek PC, Konturek S, Majka J, Zembala M, Hahn EG: Melatonin affords protection against gastric lesions induced by ischemia-reperfusion possibly due to its antioxidant and mucosal microcirculatory effects. Eur J Pharmacol 1997;122:73-77.
218. Bubenik, GA, Ayles HL, Friendship RM, Brown GM, Ball RO: Relationship between melatonin levels in plasma and gastrointestinal tissues and the incidence and severity of gastric ulcers in pigs. J Pineal Res 1998;24:62-66.
219. Benouali-Pellissier S: Melatonin is involved in cholecystokinin-in-duced changes of ileal motility in rats. J Pineal Res 1994;17:79-85.
220. Kato K, Murai I, Asai S, Komuro S, Matsuno Y, Matsukawa Y, Kurosaka H, Iwasaki A, Ishikawa K, Arakawa Y: Central effect of melatonin against stress-induced gastric ulcers in rats. Neuroreport 1997;8: 9-10.
221. Bubenik GA, Niles LP, Pang SF, Pentney PJ: Diurnal variation and binding characteristics of melatonin in the mouse brain and gastrointestinal tissues. Comp Biochem Physiol 1993;104C:221-224.
222. Bubenik GA, Dhanvantari S: The influence of serotonin and melatonin on some parameters of gastrointestinal activity. J Pineal Res 1989;7:333.
223. Petrova GA, Dedenkov AN, Levin IM: Experimental and clinical study of diagnostic usefelness of melatonin determination in cancer patients; in Cyb AF, Kvetnoy IM (eds): Regulatory Peptides and Biogenic Amines: Radiological and Oncological Aspects (in Russian). Obninsk, Russian Acad Sci, 1992, pp 58-66.
224. Kvetnoy IM, Levin IM: Diurnal melatonin excretion in gastric and rectal cancer patients (in Russian). Vopr Onkol 1987;33:29-32.
225. Vician M, Zeman M, Herichova I, Jurani M, Blazicek P, Matis P: Melatonin content in plasma, saliva and large intestine of patients with colonic cancer. 5th Can Pineal Melatonin Symp Guelph, July 13-15, 1997.
226. Anisimov VN, Popovich IG, Za-bezhinski MA: Melatonin and colon carcinogenesis. 1. Inhibitory effect of melatonin on development of intestinal tumors induced by 1,2-dimethylhydrazine in rats. Carcinogenesis 1997;18:1549-1553.
227. Pentney P: An investigation of melatonin in the gastrointestinal tract; thesis, University of Guelph, 1995.